Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.
The introduction of anti tumour necrosis factors-α (TNF-α) agents has greatly advanced the management of psoriatic arthritis (PsA). Functional disability in patients with PsA may result in significant impairment of Quality of Life (QoL), psychosocial disability and productivity loss. Although many patients respond adequately to methotrexate and other therapies, in patients who have incomplete responses, anti TNF-α agents reduce inflammation and minimise joints damage, increasing functional capacity and QoL, and decreasing the progression rate of structural damage in peripheral joints. Because of the high costs associated to anti TNF-α agents therapy, an increasing number of economic evaluations have been performed over the last few years, and several cost-of-illness and cost-effectiveness studies have been published concerning use of anti TNF-α agents in management of PsA. We performed a systematic literature review to better understand the pharmacoeconomic perspective of PsA. The pharmacoeconomic studies analysed have demonstrated the high socioeconomic burden of PsA and that TNF-α blockers treatment options provide value for money in the musculoskeletal and cutaneous manifestations of psoriatic disease.
CESP, Research Centre on Public Health, University of Milano-Bicocca, Monza, Italy. paolo.cortesi@unimi.it
Paolo A
PA
Cortesi
Luciana
L
Scalone
Lucia
L
D'Angiolella
Andrea
A
Belisari
Francesco
F
Fusco
Ignazio
I
Olivieri
Lorenzo G
LG
Mantovani
D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D019057:Quality-Adjusted Life Years; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha